Guided Growth Factor Signaling
We are engineering precision protein therapeutics that localize growth factor signaling to sites of tissue damage — unlocking the body's innate capacity for repair and regeneration without the toxicity of systemic signaling.
Platform Technology
Growth factors are among the body's most potent mediators of tissue repair. Yet systemic delivery has often failed — potent biological activity distributed across the whole body frequently causes unacceptable side effects.
Seipolt Therapeutics's platform guides and anchors growth factor activity to the tissue impacted by disease, delivering regenerative signals with spatial precision — maximizing local efficacy while minimizing systemic exposure.
The platform is broadly applicable across tissue types and organ systems, enabling a multi-indication pipeline that addresses unmet needs in major diseases that affect the lives of millions.
Key Platform Attributes
Focus Areas
Mucosal healing represents a new frontier for IBD management. We target growth factor signaling to intestinal epithelia, promoting repair when immunosuppression alone is insufficient.
By directing survival, repair and maintenance signals to the failing myocardium, we will reduce and correct the maladaptive structural changes that underly heart failure progression.
Neuroprotection and circuit repair require sustained, localized neurotrophin signaling. Our platform addresses previous failures by delivering and guiding neurotrophic support to the affected neurons.
Our Approach
Seipolt's therapeutics are designed to be complementary — not competitive — with existing treatments. For example, immunosuppressants in IBD stop gut inflammation but do not directly accelerate repair of the colorectal epithelial barrier; cholinesterase inhibitors in Alzheimer's disease enhance neurotransmission but do not promote recovery of lost cholinergic neurons and synapses; and the 'pillar' therapies for heart failure slow decline but do not directly induce proliferation of heart muscle cells. Guided growth factor signaling addresses the gaps in existing therapeutic options.
The MOAs of guided growth factors are orthogonal to existing approved therapies, enabling use on top of standard of care.
Tissue-targeting concentrates biological activity where it is needed, reducing systemic effects that have historically caused safety problems.
A single engineering platform enables rapid application across broad disease areas, with each program optimized for the specific biology and unmet need.
Programs are grounded in well-established growth factor biology with clinical precedent, reducing mechanistic risk.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Undisclosed | IBD | Tuned, disinhibited and targeted growth factor | |
| Undisclosed | Heart Failure | Undisclosed | |
| Undisclosed | Alzheimer's | Undisclosed |
All programs are investigational and have not been approved by the FDA or any other regulatory authority. Pipeline designations are for organizational purposes only.
